and functional analysis of virus-specific T cells is critical for the determination of their impact on viral containment. This is especially important in clinical trials evaluating candidate vaccines against HIV-1, because these are the first vaccines that are likely to be licensed on the basis of their ability to elicit CD8 + T cell responses. Identification of the range of effector activities of vaccine-induced T cells has assumed increasing significance, particularly because antigen-specific responses can vary depending on the nature of the immunogen used.
and functional analysis of virus-specific T cells is critical for the determination of their impact on viral containment. This is especially important in clinical trials evaluating candidate vaccines against HIV-1, because these are the first vaccines that are likely to be licensed on the basis of their ability to elicit CD8 + T cell responses. Identification of the range of effector activities of vaccine-induced T cells has assumed increasing significance, particularly because antigen-specific responses can vary depending on the nature of the immunogen used.
Historically, measures of T cell immunity have focused on the ability of CD8 + T cells to exert cytotoxic activities in vitro and have used the 51 Cr-release cytotoxic T lymphocyte assay-which is laborious, qualitative rather than quantitative, and impractical-because, for optimal detection of responses, it relies on the use of T cells isolated from fresh blood. More recently, efforts have focused on the development of more-sensitive assays, such as interferon (IFN)-g intracellular cytokine staining by flow cytometry and IFN-g ELISpot, both of which can be performed with cryopreserved peripheral-blood mononuclear cells (PBMCs) [3, 4] and can quantitate ex-vivo virus-specific memory T cells. Considerable progress has been made in the optimization and validation of these assays for use in clinical trials [5] . Nevertheless, it is unclear, in antigen-specific T cells, to what extent IFN-g secretion correlates with cytolytic activities.
Two recent studies have shown good correlation between the results of IFN-g-secretion assays [6, 7] , and a third study has shown correlation between the results of the ELISpot assay and the results of the 51 Cr-release assay [8] . However, there have been no comprehensive studies comparing the measurements of antigen-specific T cells by all 3 assay methods (i.e., ex-vivo ELISpot, ex-vivo intracellular cytokine staining, and 51 Cr release) in immunocompetent individuals. A recent study comparing these assay methods has been conducted in HIV-1-infected individuals [9] . Studies in HIV-1-infected individuals may confound the issue of whether IFN-g-secretion assays can be used as a surrogate for cytolytic activity, because it is well known that T cells from infected individuals, although able to secrete IFN-g, are dysfunctional in their ability to lyse infected cells [10] . Furthermore, HIV-1-infected individuals will obviously not be eligible for prophylactic vaccination against HIV-1. The only studies of this type in immunocompetent individuals have been performed on a very small number of individuals and have not involved the intracellular cytokine-staining assay [3, 8] . In the present study, we undertook a comparative evaluation of antigen-specific T cells secreting IFN-g and exerting cytolysis that were induced, in response to either non-HIV-1 viral infection or HIV-1 vaccination, in immunocompetent donors; responses were examined by the IFN-g ELISpot assay, the IFN-g intracellular cytokine-staining assay, and the 51 Cr-release assay. Subjects, materials, and methods. PBMCs from 22 HIVseronegative volunteers were assessed for responses to a pool of 27 8-10-mer peptides (Anaspec) representing immunodominant CD8 + T cell epitopes within cytomegalovirus, EpsteinBarr virus, and influenza (flu) (CEF); [11] ). In addition, 20 HIV-1-uninfected vaccinated study participants from a recent multicenter trial evaluating an HIV-1 canarypox vaccine (vCP1452; Aventis Pasteur) were assessed for responses recognizing HIV-1 Gag 15-mer peptides overlapping by 11 amino acids and spanning the entire HIV-1 HXB2 protein (peptides were provided by the NIH AIDS Research and Reference Reagent Program). The subjects were recruited and enrolled at the HIV Vaccine Trials Unit (in the case of CEF responders) and at multiple domestic vaccine units, through the HIV Vaccine Trials Network (HVTN) (Protocol 203). The appropriate Institutional Review Boards approved the studies, written, informed consent was obtained from all subjects, and the human-experimentation guidelines of the institutions involved in the participating vaccine-trial units were followed.
Assessments of T cell functions were conducted as are those employed in ongoing clinical vaccine trials. Donor PBMCs obtained by venipuncture were freshly stimulated with antigen in vitro, for use in the 51 Cr-release assay, or were cryopreserved and later thawed, for use in the ELISpot assay and the intracellular cytokine-staining assay. For the 51 Cr-release assay, cells were cultured for 14 days with recombinant vaccinia expressing either HIV-1 HXB2 Gag or CEF peptides at 2 mg/mL [12] . Autologous B lymphoblastoid cell lines established from each donor and pulsed with peptide pools served as target cells in conventional 4-h 51 Cr-release assay, as described elsewhere [12] . Wells containing cells with specific lysis 115%-measured as (lysis minus spontaneous lysis)/(maximum lysis minus spontaneous lysis)-after background activity was subtracted were considered to be positive.
The IFN-g ELISpot assay was performed as described elsewhere, with cryopreserved PBMCs [5] . Peptides were added at a final concentration of 1 mg/mL. Wells containing medium alone served as negative controls, and those containing 1 mg/ mL phytohemegglutinin-P (Murex) served as positive controls. Negative controls were tested in 6 replicates, whereas peptide antigens were tested in duplicate. Spots were counted by use of a CTL Analyzer and software (CTL Analyzers). Positivity was determined by use of a permutation-based criterion with a resampling adjustment for multiple comparisons, which is routinely employed in HVTN clinical trials [13] .
For intracellular cytokine staining, cryopreserved PBMCs were thawed, washed, and stimulated with either (1) staphylococcal enterotoxin B (1 mg/mL; Sigma), as a positive control, (2) pooled peptides (1-2 mg/mL of each peptide/sample), or (3) no peptide, as a negative control, as described elsewhere [14] . The following day, the cells were surface-stained with anti-CD3-allophycocyanin and anti-CD8-peridinin chlorophyll protein conjugated (Becton Dickinson) and were fixed with 1% paraformaldehyde in PBS, before intracellular staining with anti-IFN-g-fluoroscein and anti-CD69-phycoerythrin monoclonal antibodies (Becton Dickinson) was performed. Data acquisition was performed by use of a FACSCalibur flow cytometer (Becton Dickinson); 100,000-200,000 lymphocyte gated events per sample were analyzed by use of Flowjo software (Tree Star). Responses were considered to be positive when the percentage of bright IFN-g + CD69 + CD8 + T cells was twice that of the negative control.
Qualitative agreement between 2 assay methods (e.g., ELISpot vs. 51 Cr release) was assessed by standard methods for 2 ϫ 2 contingency tables [15] . Specifically, McNemar's test was used to assess whether the assay methods produced significantly different results, and the tetrachoric correlation coefficient (TCC) was used to assess the degree of positive correlation between the results of the assay methods; a nonsignificant result (P figure 1A . PBMCs from 7 (24.1%) of these 29 donors exhibited antigen-specific cytotoxicity but not ex-vivo IFN-g secretion (a representative example is shown in figure 1B) ; conversely, there were only rare instances (3 [10.3%] of 29) in which ex-vivo IFN-g-secreting T cells were detected in the absence of cytotoxicity (a representative example is shown in figure 1C) .
Although intracellular cytokine staining found ex-vivo IFNg-secreting antigen-specific CD8 + T cells in 48.8% of the donors, whereas ELISpot found them in 34.1% of them, the results of these 2 assay methods were not statistically different (P p ; McNemar's test) ( figure 2A) . Moreover, the TCC was high .07 ( ), further indicating strong correlation between the r p 0.88 2 assay methods. This finding is in agreement with recent studies of HIV-infected [7, 9] and immunocompetent [6] individuals; and discrepancies were observed when the overall frequency of IFN-g-secreting CD8
+ T cells was low. We next evaluated whether the quantities of IFN-g-secreting + /CD8 + T cells was 40% ‫ע‬ 13.5% (range, 25.8%-63.3%; data not shown). When this value was used for normalization, the ranges of IFN-g-secreting T cells detected by the 2 assay methods were similar (ELISpot, 0.02%-0.98%; intracellular cytokine staining, 0.01%-2.7%). In 7 of the 8 cases in which the frequencies of IFN-g-secreting T cells were low (ELISpot, !20 IFN-g SFCs/200,000 CD4-depleted PBMCs; intracellular cytokine staining, !0.15% IFN-g + CD69 + CD8 + T cells), the ELISpot assay and the intracellular cytokine-staining assay showed discordant results with regard to IFN-g positivity. These comparisons are difficult because of the endpoint-readout differences between the 2 assay methods, which may explain why our data are not in agreement with those reported by Karlsson et al., who have seen a lack of numeric agreement between the results of the intracellular cytokine-staining assay and those of the ELISpot assay [7] .
There was also good agreement-and no statistical difference-between the results of the IFN-g intracellular cytokinestaining assay and those of the Cr-release assay. It is noteworthy that these results are consistent with findings in HIV-1-infected individuals examined by Sun et al. [9] .
Our results suggest that, in some individuals, ex-vivo antigen-specific CD8 + T cells that secrete IFN-g may occur at very low frequencies, which makes them difficult to detect by the ELISpot assay. To address this issue, CD8 + T cells from the 22 unvaccinated responders were stimulated with CEF peptides for 14 days and were then assessed, by the ELISpot assay and by the intracellular cytokine-staining assay, for IFN-g secretion.
The results of stimulated assays with the ex-vivo IFN-g-secreting T cells from 3 representative volunteers are compared in figure 1. There were no statistically significant differences between the responses detected by the intracellular cytokinestaining assay and those detected by the 51
Cr-release assay ( , McNemar's test); moreover, all 22 individuals dem-P p .25 onstrated CEF-specific T cell responses after the day-14 stimulation, in both the ELISpot assay and the 51 Cr-release assay. Of these 22 individuals, 18 (81.8%) possessed T cell responses that were positive by the 51 Cr-release assay, 15 (68.2%) were positive by the day-0 ELISpot assay, and 21 (95.5%) were positive by the day-14 ELISpot assay. Thus, the discrepancy between the day-0 ELISpot assay and the poststimulation 51 Crrelease assay can be explained, in part, by the ex-vivo ELISpot assay's lower sensitivity, compared with that of the 51 Cr-release assay, to detect low-frequency responses in the absence of prior in vitro stimulation.
Not surprisingly, our results indicate that in vitro expansion of memory T cells enables detection of low-frequency responses. Indeed, the use of the ex-vivo ELISpot assay alone to measure antigen-specific T cell frequencies would miss ∼40% of the virusspecific cytolytic responses. However, any assay requiring in vitro expansion of responding cells has limitations, the most important being the inability to quantify antigen-specific cells and an increase in the false-positive rate. In addition, because memory T cells, rather than effector T cells, will be expanded in vitro, the cell populations studied by ex-vivo assays such as intracellular cytokine staining are qualitatively different than those studied by the traditional 51 Cr-release assay [8] . A low frequency of responder cells cannot account for the few instances (10%) in which IFN-g responses are seen at day 0 but in which no 51 Cr-release responses are detectable. This second phenomenon suggests functional heterogeneity among CD8 + T cells, with some IFN-g-secreting T cells not possessing lytic ability. Because these cells occurred at low frequency, our data suggest that the use of IFN-g-secretion assays, particularly intracellular cytokine staining, is acceptable as a surrogate for cytolytic activity. However, if measurement of all effector functions is desirable, it is prudent to explore alternate methods for the detection of ex-vivo cytolysis, to ensure that the same populations of responder cells are being assessed for both cytokine secretion and cytolytic potential.
In conclusion, we have performed the first comprehensive comparison of the results of the IFN-g ELISpot, IFN-g intracellular cytokine-staining, and 51 Cr-release assay methods in a large number of immunocompetent individuals. We have shown that the results of the ex-vivo IFN-g intracellular cytokinestaining assay correlate well with those of the ex-vivo IFN-g ELISpot assay and with those of the conventional 51
Cr-release assay-but that the results of the ex-vivo IFN-g ELISpot assay do not correlate as well with those of the conventional 51 Crrelease assay. Therefore, as a surrogate for cytolytic assays, the intracellular cytokine-staining assay is superior to the ELISpot assay.
